These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21079216)

  • 1. ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.
    Aron DC; Pogach LM
    Ann Intern Med; 2010 Nov; 153(10):JC5-9. PubMed ID: 21079216
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Intensive BP control and/or glucose control did not reduce microvascular events in hypertensive type 2 diabetes.
    Brito JP; Montori VM
    Ann Intern Med; 2012 Oct; 157(8):JC4-7. PubMed ID: 23070509
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.
    Grubina R; Smith SA
    Ann Intern Med; 2011 May; 154(10):JC5-02. PubMed ID: 21576520
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.
    Booth GL
    Ann Intern Med; 2009 Mar; 150(6):JC3-8. PubMed ID: 19306490
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Sep; 151(6):JC3-6. PubMed ID: 19755352
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Review: Intensive glucose lowering does not reduce mortality in type 2 diabetes.
    Lingegowda V
    Ann Intern Med; 2011 Dec; 155(12):JC6-4. PubMed ID: 22184705
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Review: intensive glucose control reduces surrogate, but not clinical, renal outcomes in type 2 diabetes.
    Corbett EC
    Ann Intern Med; 2012 Nov; 157(10):JC5-6. PubMed ID: 23165682
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes.
    Fonseca V
    Ann Intern Med; 2009 Jul; 151(2):JC1-12. PubMed ID: 19620156
    [No Abstract]   [Full Text] [Related]  

  • 9. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
    Bangalore S; Kumar S; Lobach I; Messerli FH
    Circulation; 2011 Jun; 123(24):2799-810, 9 p following 810. PubMed ID: 21632497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACP Journal Club. Review: Intensive blood pressure control reduces stroke, but not mortality or MI, in type 2 diabetes.
    Moist L
    Ann Intern Med; 2013 Jan; 158(2):JC5. PubMed ID: 23318339
    [No Abstract]   [Full Text] [Related]  

  • 12. ACP Journal Club. Glargine did not reduce CV events more than standard care in patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-10, JC3-11. PubMed ID: 22986402
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Screening for CAD in asymptomatic patients with type 2 diabetes did not reduce risk for cardiac events.
    Farkouh ME
    Ann Intern Med; 2009 Aug; 151(4):JC2-7. PubMed ID: 19687481
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.
    Poirier P
    Ann Intern Med; 2009 Oct; 151(8):JC4-5. PubMed ID: 19841443
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes.
    Bronson DL
    Ann Intern Med; 2010 Nov; 153(10):JC5-10. PubMed ID: 21079205
    [No Abstract]   [Full Text] [Related]  

  • 16. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
    Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
    Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 18. ACP Journal Club. Review: continuous glucose monitoring reduces HbA1c more than self-monitoring in type 1 diabetes.
    Burden AC
    Ann Intern Med; 2013 Mar; 158(6):JC9. PubMed ID: 23552900
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. A Mediterranean-style diet reduced need for glucose-lowering drugs more than a low-fat diet in type 2 diabetes.
    Mente A
    Ann Intern Med; 2009 Dec; 151(12):JC6-5. PubMed ID: 20008754
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.
    Chatterjee S; Chatterjee S
    Ann Intern Med; 2013 Apr; 158(8):JC8. PubMed ID: 23588773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.